<DOC>
	<DOCNO>NCT01341743</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety generic entecavir monotherapy combination adefovir chronic hepatitis B patient inadequate response NUC therapy</brief_summary>
	<brief_title>Efficacy Optimizing Research Chronic Hepatitis B Patients With Inadequate Response NUC Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male female age 1865 year ; Capable understand signing informed consent . Willing comply study requirement ; Serum HBsAg positive ALT &lt; 10ULN study screening ; Patients treat one nucleoside/nucleotide analogue 6 month still treatment ; History viral breakthrough genotypic resistance previous therapy ; History decompensated liver function , current signs/symptoms decompensation e.g . ascites , variceal bleeding , encephalopathy spontaneous peritonitis ; Patient history hepatocellular carcinoma ( HCC ) finding suggestive possible HCC ; Other protocol define exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>inadequate response</keyword>
	<keyword>NUC therapy</keyword>
</DOC>